Core Viewpoint - The company reported positive results from its ASC30 oral GLP-1 receptor agonist in a 28-day multi-dose escalation study, indicating significant weight loss in obese subjects [1][5]. Group 1: Study Results - In MAD cohort 2, ASC30 showed a 6.5% average weight loss after 28 days of treatment, adjusted for placebo [1]. - In MAD cohort 1, ASC30 demonstrated a 4.5% average weight loss after 28 days of treatment, adjusted for placebo [1]. - No signs of weight loss plateau were observed by day 29 [1]. Group 2: Pharmacokinetics - ASC30 at 20 mg and 40 mg showed superior oral pharmacokinetic characteristics at steady state, with a positive correlation between higher AUC and significant weight loss [2]. - Key pharmacokinetic parameters for MAD cohorts are summarized, showing Tmax of 8 hours for both cohorts, with Cmax of 272±101 ng/mL for cohort 1 and 397±274 ng/mL for cohort 2 [3]. Group 3: Safety and Tolerability - ASC30 exhibited good safety and tolerability, with only mild to moderate gastrointestinal adverse events reported [5]. - No vomiting was reported in cohort 1, while cohort 2 experienced vomiting primarily during the 10 mg dose escalation week [5]. - No serious adverse events were reported, and liver enzymes remained stable throughout the treatment [5].
歌礼制药-B(01672)在第61届欧洲糖尿病研究协会年会上报告其ASC30口服小分子GLP-1R激动剂 28天多剂量递增研究队列1和队列2的结果